TPO and autoimmune thrombocytopenic purpura: In general, TPO-RAs are preferred as the initial treatment in new/relapsed ITP patients who have not been infected with SARS-CoV-2, while prednisone at a low starting dose (usually 20 mg/day) and short duration is recommended for cases who are positive for COVID-19.